Shyam Sashikant Masrani

Title: Innovations of Shyam Sashikant Masrani in Immunotherapy

Introduction

Shyam Sashikant Masrani is an accomplished inventor based in London, GB, renowned for his contributions to the field of immunotherapy. With a total of two patents to his name, he has focused on the development of engineered Natural Killer (NK) cells that have the potential to revolutionize treatment methods for various diseases, including cancer.

Latest Patents

Masrani's latest patents include innovations in "Immune cells comprising truncated NKG2D chimeric receptors" and "Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy." Both patents disclose various embodiments relating to NK cells that express a chimeric receptor, enhancing their ability to target specific cells such as cancerous cells or those affected by infectious diseases. The patents describe NK cells that target cells expressing natural ligands of NKG2D, equipping them with transmembrane and/or signaling domains that lead to effective cytotoxic and/or cytolytic effects upon binding to target cells. Additionally, these innovations offer promising uses of NK cell compositions for disease treatment.

Career Highlights

Throughout his career, Shyam Sashikant Masrani has worked with prestigious organizations such as Nkarta, Inc. and the National University of Singapore. His deep understanding of immunology and engineering has enabled him to contribute significantly to the advancement of therapeutic technologies in the biomedical field.

Collaborations

In his professional journey, Masrani has collaborated with notable colleagues, including Jun Hao Leong and Noriko Shimasaki. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of their collective research efforts in the realm of immunotherapy.

Conclusion

Shyam Sashikant Masrani's innovative work in the development of chimeric receptors for NK cells marks a significant advancement in the treatment of diseases through immunotherapy. His dedicated efforts and collaborations reflect the ongoing necessity for innovation in medicine and highlight the potential for engineered cells to transform therapeutic practices.